• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $TNDM

    Tandem Diabetes Care Inc.

    Subscribe to $TNDM
    $TNDM
    Medical/Dental Instruments
    Health Care

    Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. Its products in development include t:sport insulin delivery system; and connected (mobile) health offerings. Tandem Diabetes Care, Inc. has a development and commercialization agreement with Dexcom, Inc. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

    IPO Year: 2013

    Exchange: NASDAQ

    Website: tandemdiabetes.com

    Peers

    $DXCM

    Recent Analyst Ratings for Tandem Diabetes Care Inc.

    DatePrice TargetRatingAnalyst
    4/10/2025$20.00Neutral
    Mizuho
    3/5/2025$45.00 → $22.00Overweight → Equal-Weight
    Morgan Stanley
    3/4/2025$35.00 → $24.00Buy → Neutral
    Citigroup
    3/3/2025$38.00 → $22.00Overweight → Equal Weight
    Wells Fargo
    2/28/2025$35.00 → $25.00Outperform → Mkt Perform
    Bernstein
    12/2/2024$45.00Equal-Weight → Overweight
    Morgan Stanley
    11/6/2024$42.00Outperform
    Bernstein
    10/4/2024$46.00Neutral
    Goldman
    10/2/2024$65.00Outperform
    RBC Capital Mkts
    8/22/2024$45.00Equal-Weight
    Morgan Stanley
    See more ratings

    Tandem Diabetes Care Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tandem Diabetes Care Announces Upcoming Conference Presentations

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025 at 10:00am Eastern Time (7:00am Pacific Time), Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 3:45pm Eastern Time (12:45pm Pacific Time), and Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 8:40am Eastern Time (5:40am Pacific Time). The presentations will be webcast live, and an archive recording will be available for 30 days. The link to the live w

      5/6/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces First Quarter 2025 Financial Results

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

      4/30/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222

      4/3/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces NEJM Publication of Positive Pivotal Study Outcomes with Control-IQ+ AID Technology in Type 2 Diabetes

      – Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine (NEJM) of positive results from the company's pivotal trial of Control-IQ+ automated insulin delivery (AID) technology in people with type 2 diabetes. The article is now available on the journal website, www.NEJM.org. Additional study findings were presented today during a symposium at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam, the Netherlands.

      3/19/25 10:00:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Launches New Control-IQ+ Automated Insulin Delivery Technology in the United States

      – Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the United States commercial launch of Control-IQ+ technology, the latest generation of the company's advanced hybrid closed-loop algorithm. Control-IQ+, compatible with both the t:slim X2 insulin pump and Tandem Mobi System, is now available for people with type 1 diabetes ages 2 years and older and adults with type 2 diabetes. Pumps pre-loaded with the updated software are now shipping to new customers, and all eligible, in-wa

      3/18/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2024 and provided its financial guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights compared to Fourth Quarter 2023 Achieved record sales as worldwide GAAP sales grew 44 percent to $282.6 million and worldwide non-GAAP sales(1) grew 21 percent to $252.4 million. Increased worldwide pump shipments by more than 25 percent. Grew the United States insulin pump market by achieving a double-digit increase in people converting from multiple daily injections. Ful

      2/26/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces FDA Clearance of Control-IQ+ Automated Insulin Delivery Technology for People with Type 2 Diabetes

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery (AID) algorithm, Control-IQ+ technology (Control-IQ+), has been cleared by the United States Food and Drug Administration (FDA) for use by people with type 2 diabetes ages 18 and older. Control-IQ+, already cleared for use by people with type 1 diabetes, builds on the company's proven Control-IQ algorithm and includes enhancements to accommodate input of expanded weight and total daily insulin ranges. Control-IQ+ is expected to be available for new and existing customers in the United States in March 2025. This press relea

      2/25/25 8:30:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Upcoming Conference Presentations

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 at 1:50pm Eastern Time (10:50am Pacific Time), Barclays 27th Annual Global Healthcare Conference on Tuesday, March 11, 2025 at 1:30pm Eastern Time (10:30am Pacific Time), Leerink Partners 2025 Global Healthcare Conference on Wednesday, March 12, 2025 at 9:20am Eastern Time (6:20am Pacific Time), and Oppenheimer 35th Annual Healthcare MedTech & Services Conference on Thursday, March 20, 2025 at 12:40pm Eastern T

      2/13/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2024 results after the financial markets close on Wednesday, February 26, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.veve

      1/15/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Enters Multi-Year Research Collaboration with UVA Center for Diabetes Technology for Development of Advanced Insulin Delivery Systems

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. The research collaboration will rely on the UVA Center for Diabetes Technology's groundbreaking work to improve care for patients with diabetes through technology-based interventions, and its successes in translating advanced automated insulin delivery (AID) algorithms into medical devices used around the world, as well as Tandem's market leading expertise

      1/7/25 9:00:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David converted options into 7,415 shares and covered exercise/tax liability with 2,739 shares, increasing direct ownership by 24% to 24,134 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/19/25 4:12:32 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Chief Technology Officer Carpenter Rick converted options into 406 shares and covered exercise/tax liability with 146 shares, increasing direct ownership by 2% to 16,392 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/19/25 4:12:22 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & Chief Admin. Officer Morrison Susan converted options into 6,903 shares and covered exercise/tax liability with 2,027 shares, increasing direct ownership by 19% to 31,189 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/27/25 5:15:55 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF FINANCIAL OFFICER Vosseller Leigh converted options into 6,903 shares and covered exercise/tax liability with 2,521 shares, increasing direct ownership by 19% to 27,225 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/27/25 5:15:43 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Strategy Officer Gasser Elizabeth Anne converted options into 6,903 shares and covered exercise/tax liability with 3,748 shares, increasing direct ownership by 82% to 7,023 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/27/25 5:15:33 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • PRESIDENT & CEO Sheridan John F converted options into 32,779 shares and covered exercise/tax liability with 13,427 shares, increasing direct ownership by 32% to 79,009 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/27/25 5:15:20 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Strategy Officer Gasser Elizabeth Anne covered exercise/tax liability with 1,261 shares and converted options into 2,141 shares, increasing direct ownership by 29% to 3,868 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/20/25 5:07:52 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & Chief Legal Officer Hansen Shannon Marie converted options into 1,969 shares and covered exercise/tax liability with 810 shares, increasing direct ownership by 10% to 12,662 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/20/25 5:07:41 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & Chief Admin. Officer Morrison Susan converted options into 2,141 shares and covered exercise/tax liability with 727 shares, increasing direct ownership by 6% to 26,313 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      2/20/25 5:07:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 28, 2025 - FDA Roundup: February 28, 2025

      For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

      2/28/25 5:00:47 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • November 7, 2023 - FDA Roundup: November 7, 2023

      For Immediate Release: November 07, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Monday, the FDA issued a Safety Communication warning consumers, health care providers, and health care facilities not to use recalled saline (0.9% sodium chloride) and sterile water medical products manufactured by Nurse Assist, LLC. On November 6, Nurse

      11/7/23 3:38:18 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      11/14/24 4:15:44 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tandem Diabetes Care Inc.

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      9/9/24 10:40:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Tandem Diabetes Care Inc.

      SC 13G - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/14/24 7:37:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/13/24 5:15:54 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/9/24 6:21:27 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      2/9/24 9:49:31 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      1/23/24 11:52:27 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      6/12/23 8:21:19 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      5/10/23 1:46:04 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Tandem Diabetes Care Inc. (Amendment)

      SC 13G/A - TANDEM DIABETES CARE INC (0001438133) (Subject)

      4/10/23 1:39:59 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Tandem Diabetes Care Inc.

      10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/30/25 4:11:29 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/30/25 4:06:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Tandem Diabetes Care Inc.

      DEF 14A - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/8/25 5:10:34 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Tandem Diabetes Care Inc.

      DEFA14A - TANDEM DIABETES CARE INC (0001438133) (Filer)

      4/8/25 5:11:06 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-K filed by Tandem Diabetes Care Inc.

      10-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      2/26/25 4:09:22 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      2/26/25 4:07:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Tandem Diabetes Care Inc.

      144 - TANDEM DIABETES CARE INC (0001438133) (Subject)

      11/21/24 11:22:52 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Tandem Diabetes Care Inc.

      144 - TANDEM DIABETES CARE INC (0001438133) (Subject)

      11/20/24 4:52:58 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Tandem Diabetes Care Inc.

      10-Q - TANDEM DIABETES CARE INC (0001438133) (Filer)

      11/6/24 4:11:29 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - TANDEM DIABETES CARE INC (0001438133) (Filer)

      11/6/24 4:08:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Operating Officer Kyrillos Jean-Claude bought $190,966 worth of shares (10,538 units at $18.12) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      3/11/25 6:06:01 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • EVP & CHIEF COMMERCIAL OFFICER Novara Mark David bought $12,364 worth of shares (532 units at $23.24) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/19/24 5:23:14 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Allen Dick bought $94,778 worth of shares (5,000 units at $18.96), increasing direct ownership by 33% to 19,962 units (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/29/23 4:10:39 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Vosseller Leigh bought $95,395 worth of shares (6,200 units at $15.39) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/13/23 4:32:57 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Hansen Shannon Marie bought $29,884 worth of shares (1,935 units at $15.44) (SEC Form 4)

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      11/13/23 4:31:41 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • SEC Form 4: Mcgroddy-Goetz Kathleen bought $21,450 worth of shares (1,000 units at $21.45), increasing direct ownership by 12% to 9,032 units

      4 - TANDEM DIABETES CARE INC (0001438133) (Issuer)

      9/19/23 4:20:41 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Tandem Diabetes Care with a new price target

      Mizuho initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $20.00

      4/10/25 12:43:51 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Tandem Diabetes Care from Overweight to Equal-Weight and set a new price target of $22.00 from $45.00 previously

      3/5/25 7:47:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Citigroup with a new price target

      Citigroup downgraded Tandem Diabetes Care from Buy to Neutral and set a new price target of $24.00 from $35.00 previously

      3/4/25 7:45:44 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Tandem Diabetes Care from Overweight to Equal Weight and set a new price target of $22.00 from $38.00 previously

      3/3/25 7:37:11 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care downgraded by Bernstein with a new price target

      Bernstein downgraded Tandem Diabetes Care from Outperform to Mkt Perform and set a new price target of $25.00 from $35.00 previously

      2/28/25 8:51:46 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Tandem Diabetes Care from Equal-Weight to Overweight and set a new price target of $45.00

      12/2/24 7:03:21 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Bernstein initiated coverage on Tandem Diabetes Care with a new price target

      Bernstein initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $42.00

      11/6/24 6:24:03 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Tandem Diabetes Care with a new price target

      Goldman initiated coverage of Tandem Diabetes Care with a rating of Neutral and set a new price target of $46.00

      10/4/24 7:48:09 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Tandem Diabetes Care with a new price target

      RBC Capital Mkts initiated coverage of Tandem Diabetes Care with a rating of Outperform and set a new price target of $65.00

      10/2/24 8:00:25 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Morgan Stanley initiated coverage on Tandem Diabetes Care with a new price target

      Morgan Stanley initiated coverage of Tandem Diabetes Care with a rating of Equal-Weight and set a new price target of $45.00

      8/22/24 7:37:30 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care

    Tandem Diabetes Care Inc. Leadership Updates

    Live Leadership Updates

    See more

    Tandem Diabetes Care Inc. Financials

    Live finance-specific insights

    See more
    • Tandem Diabetes Care Appoints Jean-Claude Kyrillos as Chief Operating Officer

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Jean-Claude "JC" Kyrillos as Executive Vice President and Chief Operating Officer, effective June 21, 2024. Mr. Kyrillos comes to Tandem with more than 20 years of global executive leadership experience in medical device, digital health, and healthcare management. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240620151195/en/Jean-Claude "JC" Kyrillos (Photo: Business Wire) "JC brings deep experience in healthcare and a great balance of technical, operational, and leadership skills from multipl

      6/20/24 9:00:00 AM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline

      Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' optio

      11/7/23 3:47:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care, Inc investors: Please contact the Portnoy Law Firm to recover your losses; November 2, 2023 deadline.

      Investors can contact the law firm at no cost to learn more about recovering their losses ​LOS ANGELES, Nov. 01, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM) investors that a lawsuit filed on behalf of investors that purchased Tandem securities between August 3, 2022 and November 2, 2022, inclusive (the "Class Period") Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' opti

      11/1/23 8:03:30 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Appoints Mark Novara as EVP and Chief Commercial Officer

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Mark Novara as Executive Vice President and Chief Commercial Officer, effective November 13, 2023. Mr. Novara comes to Tandem with extensive global healthcare experience, having served in the diabetes, medical technology, and life sciences industries for nearly 25 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231101343981/en/Mark Novara (Photo: Business Wire) "Mark is a strategic, global leader with a successful track record of driving above market business growth, while building scalab

      11/1/23 4:06:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Appoints New Chair of Board of Directors

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rebecca Robertson as Chair of its Board of Directors. Ms. Robertson, who joined Tandem's Board as an independent director in January 2019, succeeds Kim Blickenstaff, who will continue as a member of the Board. "We're deeply grateful to Kim for his instrumental contributions to Tandem since 2007, serving first as our CEO then as Chair for the past 4 years," said John Sheridan, President and Chief Executive Officer. "His strategic vision and mission-driven focus has helped to build and shape Tandem from a venture-backed start-up to a worldwide leader in dia

      2/22/23 4:15:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Parexel Appoints Peyton Howell Chief Operating and Growth Officer; Promotes FDA Veteran Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence

      BOSTON and DURHAM, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Parexel, a leading global clinical research organization (CRO), today announced the promotions of Peyton Howell to the newly-created role of Chief Operating and Growth Officer and Amy McKee, MD, to Chief Medical Officer and Global Head, Oncology Center of Excellence. These moves are designed to strengthen the company's medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales and delivery to delight customers, build repeat business and lead the market in the next phase of drug development transformation. As Chief Operating and Growth Officer, Ms. Howell will

      9/14/22 9:00:00 AM ET
      $BCRX
      $TNDM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
    • Tandem Diabetes Care Appoints Raj Sodhi to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced the appointment of Rajwant (Raj) Singh Sodhi as an independent member of its board of directors effective January 1, 2021. He will succeed Edward Cahill, who has served as a board member for the Company since May 2009. Mr. Sodhi is president of the software as a service (SaaS) business at ResMed (NYSE: RMD, ASX: RMD). He brings to the Tandem board more than 25 years of digital strategy experience, SaaS commercialization and operations across multiple industries including healthcare, financial services, and telecom. “We are pleased to w

      12/14/20 4:05:00 PM ET
      $TNDM
      $RMD
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces First Quarter 2025 Financial Results

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2025. First Quarter 2025 Highlights, Financial Results Compared to First Quarter 2024 Achieved record first quarter sales with worldwide growth of 22% Increased pump sales in the United States by 19% on a GAAP basis and 17% on a non-GAAP(1) basis, on strong shipment growth and average selling price improvement Delivered 5 point adjusted EBITDA(1) margin increase Approximately 30% of U.S. lives now covered through pharmacy benefits for Tandem Mobi Benefits of Control-IQ Technology were featured for a fourth time i

      4/30/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2025 Financial Results on April 30, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2025 results after the financial markets close on Wednesday, April 30, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2025 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register-conf.media-server.com/register/BI72222

      4/3/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter and fiscal year ended December 31, 2024 and provided its financial guidance for the year ending December 31, 2025. Fourth Quarter 2024 Financial Highlights compared to Fourth Quarter 2023 Achieved record sales as worldwide GAAP sales grew 44 percent to $282.6 million and worldwide non-GAAP sales(1) grew 21 percent to $252.4 million. Increased worldwide pump shipments by more than 25 percent. Grew the United States insulin pump market by achieving a double-digit increase in people converting from multiple daily injections. Ful

      2/26/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its fourth quarter and full year 2024 results after the financial markets close on Wednesday, February 26, 2025. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its fourth quarter and full year 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.veve

      1/15/25 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Third Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended September 30, 2024 and increased sales guidance for the year ending December 31, 2024. Third Quarter 2024 Highlights Worldwide GAAP sales increased 31 percent to $244.0 million compared to third quarter 2023; worldwide non-GAAP sales(1) increased 25 percent to $242.9 million compared to third quarter 2023. Grew worldwide pump shipments by more than 25 percent compared to third quarter 2023. Achieved year-over-year growth in new pump starts in the United States, including growth in new customers starting from multiple daily inj

      11/6/24 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce Third Quarter 2024 Financial Results on November 6, 2024

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2024 results after the financial markets close on Wednesday, November 6, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI21747dfdc3fd4a

      10/2/24 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces Second Quarter 2024 Financial Results and Increases Full Year 2024 Sales Guidance

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended June 30, 2024 and increased sales guidance for the year ending December 31, 2024. Second Quarter 2024 Highlights Worldwide GAAP sales increased 13 percent to $221.9 million compared to second quarter 2023; worldwide non-GAAP sales(1) increased 12 percent to $221.8 million compared to second quarter 2023. More than 20,000 pumps shipped in the United States, a sequential increase of 33 percent compared to first quarter 2024. Launched Tandem Mobi with Dexcom G7 continuous glucose monitoring (CGM) sensor integration in the Uni

      8/1/24 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2024 results after the financial markets close on Thursday, August 1, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BIc1efe0f41c4149

      7/11/24 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care Announces First Quarter 2024 Financial Results and Updates Full Year 2024 Financial Guidance

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2024 and increased sales guidance for the year ending December 31, 2024. First Quarter 2024 Highlights Compared to First Quarter 2023: Worldwide GAAP sales increased 13 percent to $191.7 million; worldwide non-GAAP sales increased 12 percent to $192.8 million. Worldwide pump shipments increased 9 percent to approximately 25,000 pumps from 23,000 pumps. First quarter 2024 commercial launches: Launched Tandem Mobi with Dexcom G6 continuous glucose monitoring (CGM) sensor integration in the United States. Launc

      5/2/24 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care
    • Tandem Diabetes Care to Announce First Quarter 2024 Financial Results on May 2, 2024

      Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2024 results after the financial markets close on Thursday, May 2, 2024. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2024 financial and operating results. A live webcast of the call will be available on Tandem Diabetes Care's Investor Center website located at http://investor.tandemdiabetes.com in the "Events & Presentations" section. To access the call by phone, please use this link (https://register.vevent.com/register/BI12c72cd6ea054b01881

      4/9/24 4:05:00 PM ET
      $TNDM
      Medical/Dental Instruments
      Health Care